Onconova Therapeutics Alpha and Beta Analysis
| ONTXDelisted Stock | USD 1.02 0.04 3.77% |
This module allows you to check different measures of market premium (i.e., alpha and beta) for all equities such as Onconova Therapeutics. It also helps investors analyze the systematic and unsystematic risks associated with investing in Onconova Therapeutics over a specified time horizon. Remember, high Onconova Therapeutics' alpha is almost always a sign of good performance; however, a high beta will depend on investors' risk tolerance level and may signal increased volatility and potential future overvaluation. Key technical indicators related to Onconova Therapeutics' market risk premium analysis include:
Beta 0.95 | Alpha 0.72 | Risk 0.0 | Sharpe Ratio 0.0 | Expected Return 0.0 |
Alpha is a measure of relative performance on a risk-adjusted basis, while beta measures volatility against the benchmark. The goal is to know if an investor is being compensated for the volatility risk taken. The return on investment might be better than its reference but still not compensate for the assumption of the risk.
Onconova |
Onconova Therapeutics Market Premiums
Investors always prefer to have the highest possible return on investment, coupled with the lowest possible volatility. Onconova Therapeutics market risk premium is the additional return an investor will receive from holding Onconova Therapeutics long position in a well-diversified portfolio. The market premium is part of the Capital Asset Pricing Model (CAPM), which most analysts and investors use to calculate the acceptable rate of return on investment in Onconova Therapeutics. At the center of the CAPM is the concept of risk and reward, which is usually communicated by investors using alpha and beta measures. Alpha and beta are two of the key measurements used to evaluate Onconova Therapeutics' performance over market.| α | 0.72 | β | 0.95 |
Onconova Therapeutics Fundamentals Vs Peers
Comparing Onconova Therapeutics' fundamentals to the average values of its peers is one of the most widely used and accepted methods of equity analyses. It helps to analyze Onconova Therapeutics' direct or indirect competition across all of the common fundamentals between Onconova Therapeutics and the related equities. This way, we can detect undervalued stocks with similar characteristics as Onconova Therapeutics or determine the stocks which would be an excellent addition to an existing portfolio. Peer analysis of Onconova Therapeutics' fundamental indicators could also be used in its relative valuation, which is a method of valuing Onconova Therapeutics by comparing valuation metrics with those of similar companies.
| Better Than Average | Worse Than Average | Compare Onconova Therapeutics to competition |
| Fundamentals | Onconova Therapeutics | Peer Average |
| Return On Equity | -0.84 | -0.31 |
| Return On Asset | -0.38 | -0.14 |
| Operating Margin | (89.28) % | (5.51) % |
| Current Valuation | (4.56 M) | 16.62 B |
| Shares Outstanding | 21 M | 571.82 M |
| Shares Owned By Insiders | 0.77 % | 10.09 % |
| Shares Owned By Institutions | 7.95 % | 39.21 % |
Onconova Therapeutics Opportunities
Onconova Therapeutics Return and Market Media
The Stock did not receive any noticable media coverage during the period. Price Growth (%) |
| Timeline |
About Onconova Therapeutics Beta and Alpha
For many years both, Alpha and Beta indicators are used by professional money managers as critical performance measurement tools across virtually all financial instruments including Onconova or other delisted stocks. Alpha measures the amount that position in Onconova Therapeutics has returned in comparison to a selected market index or another relevant benchmark. In other words, Alpha is the excess return on an investment relative to the performance of your selected benchmark. Beta, on the other hand, measures the relative risk of your investment.
Onconova Therapeutics Upcoming Company Events
As portrayed in its financial statements, the presentation of Onconova Therapeutics' financial position is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Onconova Therapeutics' leadership is honest, while the outside auditors are strict and uncompromising. Whatever the case, investors should always follow all of Onconova Therapeutics' public filing events to personally review all filings and be reasonable and skeptical to interpret all of the financial statements of Onconova Therapeutics. Please utilize our Beneish M Score to check the likelihood of Onconova Therapeutics' management manipulating its earnings.
| 21st of March 2024 Upcoming Quarterly Report | View | |
| 20th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 21st of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Build Portfolio with Onconova Therapeutics
Your optimized portfolios are the building block of your wealth. We provide an intuitive interface to determine which securities in a portfolio should be removed or rebalanced to achieve better diversification, find the right mix of securities that minimizes portfolio risk for a given return, or maximize portfolio expected return for a given risk level.Build Diversified Portfolios
Align your risk with return expectations
Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. You can also try the ETF Categories module to list of ETF categories grouped based on various criteria, such as the investment strategy or type of investments.
Other Consideration for investing in Onconova Stock
If you are still planning to invest in Onconova Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Onconova Therapeutics' history and understand the potential risks before investing.
| ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments | |
| Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
| Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences | |
| Money Managers Screen money managers from public funds and ETFs managed around the world | |
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
| Global Correlations Find global opportunities by holding instruments from different markets | |
| Fundamental Analysis View fundamental data based on most recent published financial statements |